التفاصيل البيبلوغرافية
| العنوان: |
Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. |
| المؤلفون: |
Katzelnick, Leah C., Zambrana, Jose Victor, Elizondo, Douglas, Collado, Damaris, Garcia, Nadezna, Arguello, Sonia, Mercado, Juan Carlos, Miranda, Tatiana, Ampie, Oscarlett, Mercado, Brenda Lopez, Narvaez, César, Gresh, Lionel, Binder, Raquel A., Ojeda, Sergio, Sanchez, Nery, Plazaola, Miguel, Latta, Krista, Schiller, Amy, Coloma, Josefina, Carrillo, Fausto Bustos |
| المصدر: |
Science Translational Medicine; 10/6/2021, Vol. 13 Issue 614, p1-13, 13p |
| مصطلحات موضوعية: |
DENGUE viruses, ZIKA virus infections, ARBOVIRUS diseases, ZIKA virus, VACCINE effectiveness, IMMUNOGLOBULINS, NATURAL immunity |
| مصطلحات جغرافية: |
NICARAGUA |
| مستخلص: |
Persistent protection: Dengue virus (DENV) and Zika virus (ZIKV) infections are mosquito-transmitted viruses that are known to elicit cross-protective antibody-mediated immune responses. It has been previously thought that initial infection with DENV or ZIKV leads to antibodies that are initially protective but wane over time to a point where they become enhancing and drive severe disease. Here, Katzelnick et al. longitudinally followed 4189 children in two cohorts in Nicaragua for up to 11 years, evaluating anti-DENV and anti-ZIKV antibody responses over time. The authors found that cross-reactive antibodies elicited by a first infection with DENV or ZIKV were unexpectedly stable over time and waned slowly after secondary infection. Together, these findings have implications for understanding natural and vaccine-elicited immunity to DENV and ZIKV. Dengue virus serotypes 1 to 4 (DENV1–4) and Zika virus (ZIKV) are mosquito-borne flaviviruses that induce both virus-specific and broadly reactive antibodies. A first DENV infection is thought to induce antibodies that wane over 2 years to titers that can subsequently enhance severe dengue disease. Secondary DENV infection with a different serotype is thought to induce stable, cross-serotype protective antibodies. Low dengue disease incidence after the recent Zika pandemic led to the hypothesis that ZIKV infection is also transiently cross protective. We investigated antibody kinetics in 4189 children up to 11 years after one and multiple DENV and ZIKV infections in longitudinal cohorts in Nicaragua. We used a DENV inhibition enzyme-linked immunosorbent assay (iELISA), which measures antibodies associated with protection against dengue and Zika disease and with enhancement of dengue disease severity. Unexpectedly, we found that overall DENV iELISA titers stabilized by 8 months after primary DENV infection to a half-life longer than a human life and waned, although gradually, after secondary DENV infection. Similarly, DENV iELISA titers were stable or rose after primary ZIKV infection but declined in individuals with histories of DENV and ZIKV infection. In contrast, kinetics of anti-ZIKV antibodies after ZIKV infection were similar regardless of prior DENV immunity. We observed heterogeneity in DENV iELISA titer, suggesting that individual antibody titer set point, rather than waning, is important for future dengue disease risk. Together, these findings change our understanding of anti-flavivirus antibody kinetics and have implications for measuring vaccine efficacy and for predicting future dengue and Zika outbreaks. [ABSTRACT FROM AUTHOR] |
|
Copyright of Science Translational Medicine is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
